Related Experiment Video
Updated: Jan 28, 2026
09:40
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
Published on: September 28, 2018
15.7K
Physical and Functional Interaction between 5-HT6 Receptor and Nova-1.
Soon-Hee Kim1, Misun Seo1, Hongik Hwang1
1Center for Neuroscience, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea.
Experimental Neurobiology
|March 12, 2019
Summary
The serotonin 5-HT6 receptor (5-HT6R) directly interacts with the splicing regulator Nova-1. This interaction impacts the molecular regulation of both proteins, affecting brain function.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- The serotonin 5-HT6 receptor (5-HT6R) is linked to cognitive and mood disorders.
- Molecular regulation of 5-HT6R and its role in brain function are not well understood.
Purpose of the Study:
- To investigate the molecular interactions and regulatory mechanisms of the 5-HT6 receptor.
- To identify proteins that directly bind to 5-HT6R.
Main Methods:
- Yeast two-hybrid assay to identify interacting proteins.
- GST pull-down and co-immunoprecipitation assays to confirm interactions.
- RT-PCR to analyze splicing activity of Nova-1 targets.
- Cellular and animal models (rat brain) were used.
Main Results:
- Human 5-HT6R directly binds to neuro-oncological ventral antigen 1 (Nova-1).
- Overexpression of 5-HT6R decreased Nova-1 splicing activity and induced Nova-1 translocation from the nucleus to the cytoplasm.
- Overexpression of Nova-1 reduced 5-HT6R activity and protein levels.
Conclusions:
- 5-HT6R and Nova-1 directly interact and mutually regulate each other's function and expression.
- Dysregulation of either 5-HT6R or Nova-1 can negatively impact the other, potentially affecting brain function.
Related Concept Videos
01:29Drug-Receptor Interactions
7.4K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.4K
01:28Drug-Receptor Interaction: Antagonist
5.0K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
5.0K
01:25Drug-Receptor Interaction: Agonist
4.0K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.0K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
653
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
653
01:30Quantitative Aspects of Drug-Receptor Interaction
1.8K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.8K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
612
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
612